FDA panel narrowly endorses empagliflozin’s cardiovascular mortality benefit
ROCKVILLE, MD. – In a 12-11 vote, a Food and Drug Administration advisory panel just barely came down in favor of the agency adding a new labeling entry to the already-approved diabetes drug...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Heart